Indian Patent Office Speeds Up Examination Process; Clears Roche’s Pegasys, Rejects Pfizer’s Caduet and Gilead’s Tamiflu
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Over the last two months, the Indian Patent Office has gone ballistic in clearing patent applications filed by multinational companies for several of their key drugs
You may also be interested in...
As Swine Flu Transcends Boundaries, Cipla Steps In To Supply Oseltamivir
MUMBAI - Known for supplies of cheap anti-retroviral drugs to major African nations, Indian drug maker Cipla has offered to make available 1.5 million dosage of Tamiflu generic oseltamivir within the next 4 to 6 weeks to control the further spread of the dreaded swine flu
As Swine Flu Transcends Boundaries, Cipla Steps In To Supply Oseltamivir
MUMBAI - Known for supplies of cheap anti-retroviral drugs to major African nations, Indian drug maker Cipla has offered to make available 1.5 million dosage of Tamiflu generic oseltamivir within the next 4 to 6 weeks to control the further spread of the dreaded swine flu
India’s Supreme Court Directs Patent Office To Review Roche's Valcyte Before Jan. 31
MUMBAI - India's Supreme Court has directed the Controller General of Patents, Designs and Trade Marks to finalize the patent validity of Roche's Valcyte (valganciclovir) before Jan. 31, 2009. Roche had filed a special leave petition that contested the Madras High Court's earlier decision that directed the Indian patent office to review the product patent granted to Valcyte in 2007